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Abstract
Marchigian-Sardinian alcohol-preferring (msP) rats exhibit innate preference for alcohol along 
with anxious phenotype. In these animals, two single nucleotide polymorphisms in position −1836 
and −2097 from the first start codon of the CRF1-R transcript have been found. Here we examined 
whether these point mutations account for the heightened anxiety-like behavior and stress 
responsiveness of msP rats. We re-derived the msP rats to obtain two distinct lines carrying the 
wild type (GG) and point mutations (AA), respectively. CRF1-R gene expression analysis 
revealed significant dysregulation of the system in the extended amygdala of AA rats. At the 
behavioral level, using the elevated plus maze, we found that both AA and GG lines had higher 
basal anxiety compared to Wistar rats. In the defensive burying test, AA rats showed decreased 
burying behavior compared to the GG and the unselected Wistar lines. Freezing/immobility did 
not differ among AA and GG but was higher than that of Wistars. The selective CRF1-R 
antagonist antalarmin (0, 10, 20 mg/kg) reduced burying behavior in Wistar animals. However, 
antalarmin (10 mg/kg) tended to increase rather than reducing this behavior when tested in the 
msP lines, an effect that appeared more marked in the GG as compared to the AA line. The 
present data suggest that rats with msP genetic background are more anxious and show different 
sensitivity to stress and CRF1-R blockade than Wistars. The point mutations occurring in the 
CRF1-R gene do not seem to influence basal anxiety while they appear to affect active responses 
to stress.
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INTRODUCTION
Dysregulation of the brain corticotropin releasing factor (CRF) system appears to be one of 
the major elements common to depression, anxiety and alcohol addiction (Markou et al. 
1998; Muller and Wurst 2004; Nemeroff and Vale 2005). CRF is a 41 amino acid peptide 
that integrates many of the endocrine, behavioral, and autonomic responses to stress 
(Sarnyai et al. 2001; Vale et al. 1981). Its arousing and anxiogenic-like properties have been 
attributed to an enhanced CRF1 receptor (CRF1-R) activation at extrahypothalamic sites 
(Heinrichs et al. 1997; Muller and Wurst 2004; Skutella et al. 1998; Zorrilla and Koob 2004) 
whereas there is no consistency in reports on the role of CRF2-Rs in anxiety (Zhao et al. 
2007). Preclinical studies using conventional and conditional knockout strategies showed 
decreased anxiety-like behavior in CRF1-R deficient mice, an effect which was independent 
of hypothalamic-pituitary-adrenocortical system function (Muller et al. 2003; Smith et al. 
1998; Timpl et al. 1998). In agreement with this, pharmacological blockade at CRF1-R 
produced anxiolytic-like effects in animal models of anxiety including reduced acoustic 
startle responses (Schulz et al. 1996), conditioned fear (Hikichi et al. 2000), and defensive 
burying (DB) behavior (Richardson et al. 2008; Zhao et al. 2007).
Increased CRF-like immunoreactivity in the extended amygdala during alcohol withdrawal 
(Merlo Pich et al. 1995; Olive et al. 2002; Roberto et al. 2010; Zorrilla et al. 2001), and 
long-term upregulation of CRF1-Rs following alcohol dependence induction have also been 
documented (Sommer et al. 2008). In addition, hyperactivation of the CRF1-R system has 
been linked to excessive alcohol drinking and vulnerability to relapse. For instance, it has 
been documented that selective CRF1-R antagonists are highly efficacious in reducing 
alcohol self-administration and stress-induced relapse to alcohol seeking in post-dependent 
rats (Ciccocioppo et al. 2009; Funk et al. 2006; Gehlert et al. 2007; Hansson et al. 2006). 
These agents also attenuated alcohol “hangover”- and withdrawal-induced anxiety-like 
behavior in rats (Gehlert et al. 2007; Overstreet et al. 2004). Altogether, these findings 
corroborate the notion that a prolonged history of alcohol exposure leads to enhanced CRF/
CRF1-R system activity that, in turn, sustains uncontrolled alcohol consumption motivated 
by the attempt to relief of negative emotional state such as anxiety and depression (Breese et 
al. 2011; Heilig and Koob 2007; Koob 2010).
Genetically selected Marchigian Sardinian alcohol preferring (msP) rats have been proposed 
as a phenocopy of animals in a post-dependent state (Ciccocioppo 2013; Ciccocioppo et al. 
2006). They have an innate high preference for alcohol, show excessive alcohol drinking [6–
8 g/kg body weight per day (Ciccocioppo et al. 2006)], are highly sensitive to stress and 
stress-induced alcohol seeking (Ciccocioppo 2013; Ciccocioppo et al. 2006), have 
depressive-like symptoms that recover following alcohol consumption (Ciccocioppo et al. 
1999) and demonstrate an anxious-like phenotype (Hansson et al. 2006). In previous studies, 
we demonstrated that msP rats have an innate hyperfunction of the CRF system that is 
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associated with the occurrence of two single nucleotide polymorphisms (SNPs) in the 
promoter region (position −1836 and −2097) of the gene encoding the CRF1-R (Gehlert et 
al. 2007; Hansson et al. 2007; Hansson et al. 2006). This genetic variation might have 
parallels in adolescent drinkers and adult alcohol-dependent subjects where similar 
mutations were found to be associated with patterns of excessive alcohol consumption 
(Schmid et al. 2010; Treutlein et al. 2006).
Starting from the original msP line we re-derived two distinct lines, one carrying the two 
point mutations (AA) and the other being the wild type line (GG). We have recently shown 
that the two observed mutations at the CRF1-R locus do not seem to play a major role in the 
expression of the msP excessive drinking phenotype, while they appear to be associated with 
decreased threshold for stress-induced reinstatement to alcohol seeking and an enhanced 
sensitivity to alcohol drinking inhibition by CRF1-R antagonism (Ayanwuyi et al. 2013). To 
follow up these initial observations, here we examined whether these mutations are 
responsible for the high sensitivity to stress and the heightened anxiety-like behavior of msP 
rats. Specifically, we first studied CRF1-R gene expression in various brain regions known 
to play a relevant role in stress, anxiety and alcohol abuse. Then, we investigated the 
phenotypic characteristics of the AA and the GG lines in preclinical models of human 
anxiety and fear comparing their behavior with that of unselected Wistar rats. Lastly, we 
evaluated their response to CRF1-R inhibition following administration of the selective 
antagonist, antalarmin.
MATERIAL AND METHODS
Animals
Subjects were adult males from two distinct sub-lines derived from the original msP line 
(65th generation). Animals were bred at the animal facility of the University of Camerino, 
Italy. Breeding started following genetic screening of the promoter region encoding for 
CRF1-Rs as previously described (Ayanwuyi et al. 2013). In brief, sequence variation AA 
versus GG in position −1836 and −2097, respectively, from the first start codon of the 
CRF1-R transcript, distinguished the two msP lines. Eighty msP rats were sequenced using 
Taqman-PCR analysis of tail DNA to identify animals carrying (AA) or not carrying (GG) 
both variants. The homozygous male and female AA and GG were then bred to obtain re-
derived lines selectively carrying the AA and the GG types. They were bred for 2 more 
generations and then animals from the third and fourth generations were used for 
experiments. Male Wistar rats (Charles River, Calco, Italy) were employed for comparisons 
between msP and heterogeneous rats because msP rats were originally selected for their high 
alcohol preference starting from a stock of heterogeneous Wistar animals. All rats (bw, 300–
400g at the time of the experiments) were housed in groups of four or five on a reverse 12-
hour light-dark cycle (lights off at 08:30 AM) at a constant temperature of 20±2°C and 
relative humidity of 45–55%, with free access to tap water and food pellets (4RF18, 
Mucedola, Settimo Milanese, Italy). Animals were handled three times before each 
experiment and used only once. All procedures followed the EU Directive for Care and Use 
of Laboratory Animals and were approved by the Ethical Committee of the University of 
Camerino, Italy.
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Drugs
The selective CRF1-R antagonist antalarmin (N-butyl-N-ethyl-[2,5,6-trimethyl-7-(2,4,6-
trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin4-yl]-amine (Webster et al. 1996) was obtained 
from the National Institute on Alcohol Abuse and Alcoholism (NIAAA/NIH). Antalarmin 
was suspended in a vehicle composed of 10% Tween 80 and distilled water and was 
administered intraperitoneally (i.p.) in a 1 ml/kg volume injection. Doses and time of 
injection were as described elsewhere (Cippitelli et al. 2012). Physiological saline was 
injected three times prior to drug testing for habituation to the experimental procedures.
Elevated plus-maze test (EPM)
To measure anxiety-like responses, the EPM test was used as previously described 
(Cippitelli et al. 2011b). The apparatus consisted of two wooden open arms (50×10 cm) and 
two enclosed arms (50×10×40 cm) which were arranged so that the similar arms were 
opposite each other, and situated 60 cm above the floor. The 5-min procedure started by 
placing each animal in the center of the maze (10 × 10 cm) facing a closed arm. The test was 
conducted in a quiet room illuminated by dim red light. Six groups of animals were used. 
Three of them (N=24, 8 GG, 8 AA msPs and 8 Wistar rats) were subjected to the test 
procedure under basal conditions, whereas the other three groups (N=22, 6–8 per group) 
were previously exposed to 60-min restraint stress in cylindrical Plexiglass tubes right 
before rats were allowed to explore the maze. The percentage of time spent exploring the 
open arms and the percentage of open arm entries were used as measures of anxiety-like 
behavior, whereas the number of entries into the closed arms was used as an indicator of 
general motor activity (Pellow et al. 1985). An entry into an arm was defined as the animal 
placing all four paws over the line marking that area. The apparatus was cleaned with tap 
water between each rat performance.
Fear conditioning test
Fear conditioning was assessed as described (Bast et al. 2001; Hansson et al. 2006) by using 
operant conditioning chambers (Med Associates Inc., Georgia, VT). On the first day 
(conditioning phase), rats were placed individually in a chamber which was programmed to 
deliver five un-signaled 1-s foot-shocks (1.0 mA) through the grid floor at 5 minute intervals 
for a 30 minute period. The time of freezing was recorded at five minute intervals. On the 
following day (expression phase), rats were placed individually in the same experimental 
context with the exception that the foot-shock was no longer released. The time of freezing 
was recorded at 1-min intervals for an 8-min period. Data are reported as total time spent 
freezing during six consecutive 5-min blocks of the conditioning phase and 8-min re-
exposure to the context previously associated with foot-shock (expression). N=26 rats (8 
Wistar, 9 GG and 9 AA msP rats) were employed in this experiment.
Shock-probe defensive burying (DB) test
The shock-probe DB test (Pinel and Treit 1978) was carried out as previously described 
(Cippitelli et al. 2011a). The DB apparatus was a modified home cage with 5 cm high wood 
chip bedding material evenly distributed throughout the cage. One side of the cage contained 
a round hole of diameter 0.75 cm through which a probe delivering 1.5 mA electric shock 
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was inserted. As for EPM, the DB test was conducted in a quiet room illuminated by dim red 
light. Rats were kept in the quiet test room for at least three hours on the day before the 
experiment for the purpose of acclimatization. On the test day, the shock probe was 
connected to a shocker instrument (Med associates, Inc.) and remained turned on throughout 
the test. Upon first contact with the shock-probe, the burying behavior of the rat was 
recorded for 15 minutes. Contacts with the probe resulted in the rat piling bedding material 
with treading-like movements of the forepaws and shoveling movements of the head, often 
directed toward the shock-probe. The latency to start burying and the duration of burying 
were dependent variables that served as measures of anxiety-/fear-like behaviors. The chip 
bedding material was changed before each rat performance. Three experiments were carried 
out by using this paradigm. DB behavior was first examined in the two msP rat lines (N=8 
GG and N=8 AA) and compared to that of Wistar rats (N=8) and Wistar rats previously 
exposed to 60-min restraint stress (W/Restraint, N=8). In a second experiment, the effect of 
the selective CRF1-R antagonist antalarmin was tested. Antalarmin was administered to 
Wistar (N=23, 7–8 per treatment dose), GG msP (N=47, 14–17 per dose) and AA msP 
(N=40, 13–14 per dose) rats at doses of 0, 10 and 20 mg/kg, 30 min before the onset of the 
DB test. Finally, antalarmin was tested in additional Wistar rats (N=29) previously exposed 
to 60 min restraint stress. The CRF1-R antagonist (0, 10, 20 mg/kg) was administered 30 
min prior to restraint and behavioral performance in the DB test was compared with that of 
Wistars receiving antalarmin 0 mg/kg not exposed to stress.
Brain collection, reverse transcription and quantitative real time polymerase chain 
reaction (qPCR)
Brains (N=24) from Wistar (N=8), GG msP (N=8), AA msP (N=8) were collected and snap-
frozen with isopentane for measurements of CRF1-R mRNA levels. The brains were sliced 
on a cryostat, and bilateral punches (300 µm thickness, 2 mm diameter) were collected from 
the medial region of the prefrontal cortex (mPFC), septum, nucleus accumbens (NAcc), bed 
nucleus of the stria terminalis (BNST), amygdala (Amy), paraventricular nucleus of the 
hypothalamus (PVN) and median raphe nucleus (MRN). Reverse transcription and qPCR 
were conducted as described elsewhere (Barbier et al. 2013). In brief, RNA was extracted 
and purified from brain tissue using the PureLink™ RNA Mini Kit (Ambion, Austin, TX) 
following the manufacturer’s instructions. cDNA was reverse transcribed from total RNA 
using the Superscript III First Strand Synthesis System (Invitrogen, Carlsbad, CA). Gene 
expression levels were determined by qPCR using a TaqMan Universal PCR Master Mix 
(Applied Biosystems Inc., Foster City, CA). cDNA concentrations of the CRF1-R transcript 
(CRF1-R) were calculated according to the relative quantification (ΔΔCt) method, corrected 
for differences in PCR efficiency, normalized to glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh). Primers used were as follows: TaqMan qPCR utilized commercially available 
CRF1-R (Rn00578611_m1) and Gapdh (Rn99999916_s1) primer/probe sets, (Applied 
Biosystems Inc., Foster City, CA), with PCR conditions according to the manufacturer 
protocol. Data as reported as percentage of control (Wistar group).
Statistical analysis—EPM data were analyzed by means of a two-way analysis of 
variance (ANOVA) where rat “line” and “restraint” were between-subject factors. Analysis 
of DB and fear conditioning data were carried out by means of one-way ANOVA with the 
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rat “line” as between-subject factor. To evaluate CRF1-R mRNA expression levels, one-way 
ANOVA was also used to analyze the brain regions independently. The effect of antalarmin 
was analyzed by means of a two-way ANOVA with “rat line” and “drug treatment” as the 
between-subject factors. The effect of antalarmin on burying behavior of Wistar rats 
previously exposed to restraint was analyzed separately using one-way ANOVA with 
“group” as a between-subject factor. Accepted p-level was p<0.05 for behavioral data and 
p<0.01 for gene expression data. When appropriate, analyses of behavioral data were 
followed up by Fisher’s least significant difference (LSD) post hoc tests while qPCR data 
were followed by Tukey-Kramer post hoc tests.
RESULTS
CRF1-R gene expression levels in AA, GG and Wistar rats
Expression of the CRF1-R gene was evaluated on a network of structures densely populated 
in CRF1-Rs (Contarino and Gold 2002) or previously reported to be associated with anxiety- 
and fear-like behaviors as well as pathophysiological response to stress (De Boer and 
Koolhaas 2003). MsP lines showed different expression in CRF1-R mRNA levels in the 
Amy [F(2,20)=47.2, p<0.001] and the BNST [F(2,19)=7.8, p<0.01] compared to the 
unselected Wistar strain (Table 1). Post hoc testing revealed robust upregulation in the Amy 
of both GG and AA msP lines (p<0.001) and marked downregulation of CRF1-R in the 
BNST of the AA msP line compared to the Wistar line (p<0.01). A trend to an increased 
CRF1-R mRNA levels was seen in the mPFC [F(2,21)=3.6, p<0.05 ] while no significant 
alterations were observed in the Septum [F(2,19)=1.1, NS], the NAcc [F(2,19)=0.6, NS], the 
PVN [F(2,19)=2.0, NS] and the MRN [F(2,14)=1.8, NS].
Basal anxiety levels and stress-induced anxiety in the EPM test
EPM results indicated that under basal conditions both GG and AA msP lines showed 
increased anxiety-like behavior compared to unselected Wistar rats. However, no significant 
differences between the two alcohol preferring lines were observed. Further, EPM data 
showed that exposure to restraint stress produced heightened anxiety levels in all three rat 
lines examined. Overall ANOVA for the percentage of time spent exploring the open arms 
revealed a robust main effect of “line” [F(2,40)=14.1, p<0.001] accompanied by main effect 
of “restraint” [F(1,40)=16.4, p<0.001] but not by a significant interaction of “line x restraint” 
[F(2,40)=1.9, NS]. Post hoc analysis indicated that the collapsed variable of line was 
decreased in both GG and AA msP vs. Wistar rats (p<0.001). Similarly, restrained Wistar 
animals showed anxiogenic-like behavior compared with non-restrained (p<0.001, Figure 
1A). Results of ANOVA with regard to the percentage of open arm entries paralleled to a 
lower extent those of time spent exploring the open arms. Thus, a main effect of “line” 
[F(2,40)=5.8, p<0.01] was accompanied by main effect of “restraint” [F(1,40)=6.3, p<0.05] 
with no significant interaction “line x restraint” [F(2,40)=0.4, NS]. Post hoc comparisons of 
the collapsed variable of “line” showed increased percentage of entries onto the open arms 
for Wistar vs. both the AA (p<0.01) and the GG (p<0.05) msP lines with restraint stress 
significantly altering this measure (p<0.05, Figure 1B). However, the observed difference in 
these anxiety-related variables was associated to a different number of entries into the closed 
arms since ANOVA showed overall significant difference for the main effect of “line” 
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[F(2,40)=17.8, p<0.001] in absence of significant “restraint” effect [F(1,40)=3.0, NS] or 
interaction “line x restraint” [F(2,40)=2.0, NS]. Specifically, crossings onto closed arms were 
decreased in the GG and the AA lines (p<0.001 for both) vs. Wistars (Figure 1C).
Freezing response in the acquisition and recall of fear conditioning
The fear conditioning test produced a pattern of freezing response that was characteristic of 
an anxiogenic-like phenotype for both the GG and the AA msP lines. Overall ANOVA 
showed a markedly higher level of freezing behavior during both conditioning [F(2,23)=21.4, 
p<0.001] and expression [F(2,23)=4.5, p<0.05] phases of the test. On post hoc analysis, fear 
reaction was increased in GG and AA msP rats as compared with the Wistar strain 
[acquisition: p<0.001 for both (Figure 2A), expression: p<0.05 for both (Figure 2B)].
Defensive burying response in AA, GG, Wistar and previously restrained Wistar rats
Overall ANOVA comparing Wistar, GG, AA msPs, and Wistar rats previously exposed to 
60-min restraint stress revealed a significant difference in the total time spent burying 
[F(3,28)=7.4, p<0.001]. Pairwise comparisons indicated higher burying time in Wistar rats 
compared to GG (p<0.05) and AA (p<0.001). Noteworthy, the burying time of AA was also 
lower (p<0.05) compared to that of GG rats. Wistar rats subjected to restraint, showed 
decreased burying, compared to non-restrained Wistars (p<0.01), suggesting that exposure 
to stress decreases this stress-coping behavior (Figure 3A). When the latency to start burying 
was evaluated (Figure 3B) overall ANOVA showed increased latency to start burying 
[F(3,28)=4.9, p<0.01]. Post hoc analysis revealed a significant higher latency to bury in the 
AA rats compared to GG or non-restrained Wistars (p<0.05 and p<0.01, respectively). A 
significant difference between W/restraint and non-restrained Wistar groups was also 
observed (p<0.05).
Defensive burying response in AA, GG and Wistar rats following antalarmin treatment
Overall ANOVA revealed changes in the total duration of defensive burying behavior with a 
significant main effect of “treatment” [F(2,101)=3.8, p<0.05], significant main effect of “line” 
[F(2,101)=4.3, p<0.05] and “treatment x line” interaction [F(4,101)=2.6, p<0.05]. In Wistar rats 
post hoc analysis indicated that, compared to vehicles, 20 mg/kg of antalarmin significantly 
(p<0.01) reduced the duration of burying (Figure 4A). In the GG line 10 mg/kg of 
antalarmin significantly increased the burying time (p<0.05) compared to vehicles. At the 
higher dose (20 mg/kg) antalarmin did not appear to evoke significant effects. In the AA line 
antalarmin showed a trend to an increase in burying time but statistical difference was not 
reached.
When the latency to start burying was evaluated (Figure 4B), ANOVA revealed no 
significant overall effect of treatment [F(2,101)=0.8, NS] although a significant effect of rat 
“line” was observed [F(2,101)=6.3, p<0.01]. Finally, no “treatment x line” interaction was 
displayed [F(4,101)=1.6, NS]. Post hoc comparisons revealed increased latency to initiate 
burying in AA rats compared to Wistars (p<0.05) and GG msPs (p<0.01).
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Defensive burying response in Wistar rats exposed to restraint following antalarmin 
treatment
One-way ANOVA, conducted in unselected Wistar rats exposed to restraint following 
antalarmin treatment and a group of Wistars receiving the vehicle of antalarmin and not 
exposed to restraint, revealed changes in the total duration of defensive burying behavior 
[F(3,25)=8.1, p<0.001]. Post hoc analysis indicated an expected reduction in time of burying 
of the restrained group non-pretreated with antalarmin as compared to the group not exposed 
to stress (p<0.01). In a manner similar to the effects of antalarmin observed in the msP lines, 
group comparisons also indicated that treatment with 10 mg/kg antalarmin prior to restraint 
significantly increased the burying time (p<0.05) compared to the restrained group receiving 
antalarmin 0 mg/kg. At the higher dose (20 mg/kg) antalarmin did not appear to evoke 
significant effects (Figure 5).
Latency to initiate burying was also changed [F(3,25)=4.7, p<0.01] with the antalarmin 20 
mg/kg group being substantially increased as compared to the other treatment groups. Mean
±SEM latency to start burying for the 4 groups were 287.4±61.9 (antalarmin vehicle/No-
Restraint), 358.9±141.3 (antalarmin vehicle/Restraint), 116.3±18.1 (antalarmin 10/Restraint) 
and 611.4±96.5 seconds (antalarmin 20/Restraint).
DISCUSSION
The gene expression analysis reported here indicated significant CRF1-R over-expression in 
the amygdala of both AA and GG rats compared to the progenitor Wistar line. Although 
binding data on brain CRF1-R protein levels in AA and GG rats are not provided here, this 
elevated CRF1-R expression may reflect increased density of CRF1-R sites in numerous 
brain regions, including different portions of the amygdala, as we previously demonstrated 
in the original msP line from which the AA and GG lines were derived (Hansson et al. 
2006). Increased CRF function in the CeA has been linked to excessive anxiety-like 
behavior in the EPM (Ciccocioppo et al. 2014; Ji et al. 2007). In excellent agreement with 
this evidence, in the EPM test we found that the AA and GG lines express lower exploratory 
behavior and spent less time in the open arm of the maze compared to heterogeneous Wistar 
rats. Closed arm entries were also reduced in AA and GG rats compared to Wistars. This is 
consistent with previous published data showing that exploratory behavior in msP rats is 
reduced under condition of novelty (Hansson et al. 2006). On the other hand, the two 
examined polymorphisms at CRF1-R locus did not seem to determine the innate anxiogenic 
phenotype of our two lines of alcohol preferring animals. In fact, no differences between AA 
and GG rats were observed in the EPM test. Previous studies have shown that msP rats from 
which the AA and the GG were derived are highly sensitive to stress exposure (Ciccocioppo 
et al. 2006; Hansson et al. 2006). Hence, we decided to expand our EPM study by looking at 
whether the observed point mutations in the CRF1-R gene would play a role in enhanced 
anxiety resulting from exposure to a stressful stimulus. The test was therefore replicated in 
GG, AA and unselected Wistars previously subjected to 1 hour restraint stress. As expected, 
stress exposure elicited a considerable anxiogenic-like response in Wistar rats that showed 
levels of anxiety comparable to those seen in the AA and GG lines without restraint. A trend 
towards increased anxiety-like behavior was also observed in AA and GG rats that showed 
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further decreased time spent in the open arms and entries onto the open arms of the maze. 
Although the AA line appeared to be more responsive to the restraint stress than the GG 
line, statistical analysis did not show significant line difference. We argued that possible 
floor effects may have attenuated the possibility to detect potential differences between the 
lines. Therefore, to better address this issue we studied the behavior of AA and GG rats in 
the fear conditioning model which reflects fear-like responses generated by exposure to 
stressful environmental conditions rather than generalized anxiety disorders. Results showed 
that both AA and GG lines subjected to contextual fear conditioning showed higher time of 
freezing (complete absence of somatic motility except for respiratory movements) as 
compared to Wistar rats during both the acquisition and recall sessions with freezing levels 
being indistinguishable between the two lines. It is known that neuronal processing in the 
amygdala is important for classical fear conditioning to contextual as well as explicit 
conditioned stimuli (Goosens and Maren 2001; LeDoux 2000) and work carried out using 
electric shock stress has suggested that the central portion of the amygdala is predominantly 
involved in the expression of passive behavioral coping (Legradi et al. 2007; Roozendaal et 
al. 1997). On the other hand, the basolateral amygdala has been shown to be implicated in 
the acquisition of fear-related behaviors (Bijlsma et al. 2011). Hence, although the longer 
acquisition latency observed in both AA and GG lines compared to the Wistar is an 
important evidence of spontaneously increased inhibitory/passive response to stress in msP 
rats, the negative finding in the fear conditioning test (no differences between AA and GG 
rats) nicely correlates with the over expression of the CRF1-R gene found in the amygdala 
of both msP rat lines compared to Wistars and suggests the lack of a functional role for the 
examined polymorphisms in passive fear response.
An important difference in CRF1-R expression was found in BNST, where AA rats showed 
significantly lower expression levels of the transcript than the Wistar group. The BNST, is 
an important structure implicated in the integration and processing of stress responses, plays 
a role pathological anxiety (Hammack et al. 2004; Sparta et al. 2013) and is a critical 
neuroanatomical substrate for stress-induced reinstatement of drug seeking, where CRF 
plays a major role (Erb and Stewart 1999; Silberman and Winder 2013). This suggests that 
CRF neurotransmission in the BNST is involved in triggering active reactions to stress. 
Moreover, activation of the CRF system in the BNST seems to contribute to the expression 
of defensive behavior and CRF antagonists directly injected into this nucleus attenuate it 
(Jasnow et al. 2004). Finally, it has been reported that administration of a CRF antagonist 
into the BNST did not attenuate phasic but blocked sustained fear behaviors (Davis et al. 
2010), indicating that this structure may be recruited to regulate forms of anxiety associated 
to a more long-lasting state of apprehension rather than transient fear. Based on this 
background, we postulated that the different organization of the CRF system in the BNST of 
AA rats would influence active stress coping responses in this rat line.
To test this hypothesis we used the shock-probe DB model originally described by Pinel and 
Treit (1978). This model seems to be particularly appropriate to examine whether the 
observed SNPs in the CRF1-R gene would have functional relevance as it requires rats to 
engage in an active behavioral response to stress (to bury an electrified probe) and is highly 
dependent on the extrahypothalamic CRF system (Basso et al. 1999; De Boer and Koolhaas 
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2003). For instance, CRF administration increases DB in rats (Diamant et al. 1992), and 
CRF antagonists block this response (Basso et al. 1999; Richardson et al. 2008). In the DB 
test we found that the AA line had the lowest total time of burying in a single 15-min trial as 
well as the highest latency to start burying followed by the GG line and then the unselected 
Wistar rats. This result is indicative of the fact that the examined polymorphisms in the 
CRF1-R gene could play a role in regulating active forms of stress avoidance behavior. To 
some extent the decreased burying response observed in AA rats, and also partly in the GG 
line, contradicts the common notion that higher stress sensitivity and increased anxiety 
positively correlates with enhanced burying response DB test (De Boer and Koolhaas 2003; 
Korte et al. 1994). To reconcile this apparent paradox, we subjected Wistar rats to restraint 
stress prior to the DB and we found that after this stress manipulation, the burying behavior 
of Wistar rats was dramatically reduced and similar to that observed in the AA line. These 
data suggest that when animals are in a state of excessive stress, either innate as in AA and 
GG rats or evoked following physical restraint, they lose the ability to engage in active 
reactions to stress. Evidence linking these behavioral responses to over-function of the CRF 
system also exists. For example, it has been documented that CRF1-R agonist stressin1-A 
elicited burying reactions at low doses but increased freezing at 25-fold higher doses 
switching the behavior of rats from active to passive (Zhao et al. 2007). Another study 
showed that cortagine, a selective CRF1-R agonist, administered bilaterally into the cerebral 
ventricles of rodents evoked anxiogenic-like effects in a model of defensive behaviors by 
dose-dependently enhancing passive avoidance and freezing, while burying was decreased 
(Tovote et al. 2010).
To prove that DB response was under the control of the CRF1-R system we administered 
antalarmin. Interestingly, blockade of CRF1-R resulted in opposite responses. Confirming 
previously published data in Wistar rats it reduced the burying behavior (Heinrichs et al. 
2002; Richardson et al. 2008). On the other hand, antalarmin increased the burying response 
in GG and AA rats at the low dose, an effect that disappeared at higher dosages. This 
reversal of a previously inhibited burying behavior could be attributed to the ability of 
antalarmin to contrast the abnormally heightened anxiety/stress state of msP rats bringing it 
back to normal levels thus enabling re-gain of active stress coping response (i.e., increase in 
burying behavior). Additional evidence that a low antalarmin dose administered to 
unselected Wistar animals exposed to acute restraint stress produced a similar defensive 
burying response than observed in the msP lines strengthens this view. In agreement, a more 
complete blockade of the CRF1-Rs as that obtained by administering antalarmin at high 
doses led to a full anxiolytic effect that in turn resulted in burying reduction.
At present it is unclear how to reconcile the hypersensitivity to stress observed in AA and 
GG rats with reduced expression of CRF1-R transcript in the BNST. It is possible that 
downregulation of the transcript is part of a compensatory change in CRF1-R expression 
aimed at balancing the over-function of the CRF system in the CeA of msP rats (Hansson et 
al. 2006; Herman et al. 2013). In this respect, the more pronounced reduction in CRF1-R 
transcript associated with the polymorphisms found in AA rats may be viewed as an 
additional compensatory mechanism occurring in this rat line. For instance, it may be argued 
that the low CRF1-R transcript level in AA rats may reflect changes at neurocircuitry levels 
Cippitelli et al. Page 10
Psychopharmacology (Berl). Author manuscript; available in PMC 2016 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(i.e., reduction in the number of CRF1-R positive neurons in the BNST). Several evidences, 
in fact, indicate profound reorganization of this nucleus as a result of exposure to stress. For 
instance, it has been shown that in the BNST, stress can have a major impact on dendritic/
synaptic remodeling (Pego et al. 2008), blunts neuronal plasticity (Conrad et al. 2011) and 
can change GABAergic and glutamergic innervation of the nucleus (Ventura-Silva et al. 
2012). Additional studies will have to be performed to understand the impact of CRF system 
over-activation and CRF1-R transcript polymorphisms occurring in the AA line on the 
neuroanatomical and functional organization of the BNST.
In conclusion, two major findings are outlined here. First, we show that two previously 
identified point mutations at the CRF1-R gene locus do not seem to play a major role in 
basal anxiety or in passive behavioral responses to stress. However, they appear to 
contribute to a reduced capacity to actively react to stress. Secondly, these findings may 
have important pharmacogenetic implications because they support the notion that 
polymorphisms at CRF1-R locus correlate with stress hypersensitivity, and possibly with 
specific forms of anxiety.
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Figure 1. 
Elevated anxiety-like behavior of both GG and AA lines derived from the original msP line 
as assessed in the elevated-plus maze (EPM) test. GG (N=8) and AA (N=8) msP rats show 
lower (A) time spent exploring open arms and (B) open arm entries as compared with 
unselected Wistar (N=8) rats in basal (no-restraint) conditions. 1-hour restraint stress 
produces anxiogenic effects in all lines examined (Wistar N=6, GG msP N=8, AA msP 
N=8). The elevated anxiety of the msP lines is accompanied by (C) reduced exploration of 
the maze. Values are presented as mean percent (%, ±S.E.M.) of open arm time and entries, 
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and mean (±S.E.M.) number of closed arm entries. *p<0.05, **p<0.01 and ***p<0.001, 
significant difference between both msP lines and the Wistar rat strain. **(AA) 
p<0.01,*(GG) p<0.05, significant difference between the AA and the GG line vs. the Wistar 
line, respectively. #p<0.05, ###p<0.001, difference from non-restrained groups. For detailed 
statistics, see Results.
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Figure 2. 
Increased time of freezing in both the lines GG and AA msPs during (A) conditioning 
(acquisition) and (B) expression (recall) sessions in a contextual fear conditioning paradigm. 
Data are the mean ± SEM seconds (sec) of freezing (Wistar N=8, GG msP N=9 and AA msP 
N=9) during six consecutive 5-min blocks of fear conditioning or 8-min re-exposure to 
context previously associated with foot-shock. *p<0.05, ***p<0.001, difference from the 
Wistar line. For detailed statistics, see Results.
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Figure 3. 
15-min defensive burying (DB) performance of Wistar (N=8), GG msP (N=8), AA msP 
(N=8) and restrained Wistar (W/Restraint, N=8) rat lines. The AA line exhibits (A) 
decreased time of burying and (B) increased latency to bury as compared to the GG msP line 
and unselected Wistar rats. W/Restraint group performs in a similar way than AA. Time of 
burying and latency to bury values are expressed in mean (±S.E.M.) seconds (sec). *p<0.05, 
**p<0.01, ***p<0.001, significant difference from the Wistar line. #p<0.05, difference 
between the AA and the GG line. For detailed statistics, see Results.
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Figure 4. 
Effect of the selective CRF1-R antagonist antalarmin (0, 10, 20 mg/kg, i.p.) in the DB 
performance of Wistar (N=23), GG (N=47) and AA msP (N=40) rats. (A) Antalarmin dose-
dependently decreases the total time of burying during the 15-min test in unselected Wistars 
and increases this variable in the GG line when injected at a dose of 10 mg/kg. (B) Latency 
to initiate burying is increased in the AA msP animals. Time of burying and latency to bury 
values are expressed in mean (±S.E.M.) seconds (sec); *p<0.05, **p<0.01, difference from 
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antalarmin vehicle (0 mg/kg); #p<0.05, ##p<0.01, difference from the AA msP line. For 
detailed statistics, see Results.
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Figure 5. 
Effect of the selective CRF1-R antagonist antalarmin (0, 10, 20 mg/kg, i.p.) in the DB 
performance of Wistar rats (N=29, 6–8 per group) previously exposed to 60 min restraint 
stress. Antalarmin or vehicle (0 mg/kg) was administered 30 min prior to restraint that 
preceded the 15 min DB performance. Vehicle of antalarmin was injected to a rat group not 
exposed to restraint that served as control. Time of burying values are expressed in mean 
(±S.E.M.) seconds (sec); **p<0.01, ***p<0.001 difference from control; #p<0.05 difference 
from rats exposed to restraint following antalarmin 0 mg/kg treatment. For detailed 
statistics, see Results.
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Table 1
Expression of the CRF1-R gene within a network of brain structures including the medial region of the 
prefrontal cortex (mPFC), septum, nucleus accumbens (NAcc), bed nucleus of the stria terminalis (BNST), 
amygdala (Amy), paraventricular nucleus of the hypothalamus (PVN) and median raphe nucleus (MRN) in 
Wistar (N=8), GG msP (N=8), AA msP (N=8) lines.
Rat line
Brain Structure Wistar GG msP AA msP
mPFC 100.9±5.3 136.8±9.2 125.0±12.8
Septum 104.7±12.9 109.3±8.2 90.8±8.6
NAcc 100.3±3.3 123.2±12.8 106.1±21.1
BNST 102.3±8.7 80.8±5.6 62.8±2.7**
Amy 102.0±7.7 187.0±4.7*** 188.8±8.7***
PVN 100.4±4.0 106.8±5.5 116.3±6.2
MRN 115.6±34.9 119.9±18.2 112.1±8.0
Data are reported as mean (±S.E.M) percent (%) of control (Wistar group).
**p<0.01,
***p<0.001 difference from the Wistar group. For detailed statistics, see Results.
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